Notice of Interim Results

RNS Number : 7981P

Allergy Therapeutics PLC

23 February 2016

 



23 February 2016

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Notice of Interim Results

Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will issue its interim results for the six month period ended 31 December 2015 on Tuesday 8^th March 2016.

A meeting for analysts will be held at 9:30am at the offices of Panmure Gordon at 1 New Change, London, EC4M 9AF. Manuel Llobet, Chief Executive Officer, and Ian Postlethwaite, Chief Financial Officer, will provide an update on the Company with a Q&A session which will be accessible remotely via a live conference call. The details of the call will be provided in the statement on Tuesday 8^th March.

- ENDS -

For further information please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

Panmure Gordon

[phone]

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton

[e-mail]

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information please see www.allergytherapeutics.com.

 

END

 

 

NORDLLFLQLFXBBD